Outcomes of tumour related epilepsy in a specialised epilepsy surgery unit

Kim, Jun; Radjadurai, S.; Rahman, Zebunnessa; Hitos, Kerry; Ghattas, Samer; Gomes, Lavier; Wong, Chong; Bleasel, Andrew; Dexter, Mark

doi:10.1016/j.jocn.2018.01.062

Cited by 4 publications

(3 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, it is evident that the mean age has decreased since the finding was made and represents a data that accompanies what has been described by recently published epidemiological studies [16][17][18], such as in the CBTRUS Statistical Report of the present year. However, the debate on these data is still ongoing [19][20][21], since until a few years ago it was believed that these types of tumors were more prevalent in men, with mortality also higher in men. It is shown, however, that for both sexes, this index is higher in the group of older adults [22][23][24], irrespective of the fact that the mortality described for this study of Colombian subjects is 18.6% of all patients compared to 20% for the US population [25][26][27][28].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Epidemiological Characteristics of Primary Tumors 0f the Central Nervous System According to Anatomical Location and Type of Lesion in a Level IV Hospital in Colombia in the Period Between 2008-2019

Rodriguez¹

2022

Arch Clin Trial & Case Rep.

View full text Add to dashboard Cite

Introduction: According to figures from GLOBOCAN 2020, tumors of the central nervous system have an incidence of 1.6% with a mortality of 2.5%. For Colombia, 1,901 new cases were registered, with an incidence of 1.7% and 1,650 deaths, with a mortality of 3%. Aim: To describe the epidemiological characteristics of patients diagnosed with primary tumors of the central nervous system at a central military hospital in the period between 2008-2019. Materials and methods: A cross-sectional descriptive study was proposed, collecting data from the period between 2008 and 2019. 177 cases met these criteria, of which the sociodemographic variables were estimated, and the survival for these was determined through the Kaplan-Meyer analysis of the tumors. Results: The average 5-year survival for men is 22% and for women 27%. 18.6% of the 177 patients diagnosed with primary brain tumors in the study died after histopathological diagnosis, of which 60.6% were men and 39.4% women. Conclusions: The highlighted sociodemographic aspects represent a contribution to the generation of new evidence for primary tumors of the central nervous system in our country.

show abstract

Section: Discussionmentioning

confidence: 99%

“…On the other hand, the description of the clinical manifestations was not included within the statistical analysis. It is shown that headaches, and seizures [17,20,42,43] are frequent, presenting in more than 70% of the patients as soon as the tumors occur.…”

Section: Discussionmentioning

confidence: 99%

Epidemiological Characteristics of Primary Tumors 0f the Central Nervous System According to Anatomical Location and Type of Lesion in a Level IV Hospital in Colombia in the Period Between 2008-2019

Rodriguez¹

2022

Arch Clin Trial & Case Rep.

View full text Add to dashboard Cite

show abstract

“…On the other hand, anti-tumor treatments often result in an improvement in epileptic seizure control. Surgical excision of the tumor represents one of the first treatment options [ 4 , 5 ]. Depending on the glioma entity, adjuvant chemoradiation can have further benefits in the treatment of TAE [ 6 , 7 ].…”

Section: Introductionmentioning

confidence: 99%

The Antiepileptic Drug Oxcarbazepine Inhibits the Growth of Patient-Derived Isocitrate Dehydrogenase Mutant Glioma Stem-like Cells

Trong

Jungwirth

Unterberg

et al. 2023

Cells

View full text Add to dashboard Cite

Patients diagnosed with isocitrate dehydrogenase mutant (IDHmut) gliomas suffer frequently from seizures. Although the clinical course is less aggressive than that of its IDH wildtype counterpart, recent discoveries have shown that epileptic activity can promote tumor proliferation. However, it is not known if antiepileptic drugs confer additional value by inhibiting tumor growth. In this study, the antineoplastic properties of 20 FDA-approved antiepileptic drugs (AEDs) were tested in six patient-derived IDHmut glioma stem-like cells (GSCs). Cell proliferation was assessed using the CellTiterGlo-3D assay. Two of the screened drugs (oxcarbazepine and perampanel) demonstrated an antiproliferative effect. A subsequent eight-point dose–response curve proved the dose-dependent growth inhibition for both drugs, but only oxcarbazepine reached an IC50 value below 100 µM in 5/6 GSCs (mean 44.7 µM; range 17.4–98.0 µM), approximating the possible cmax for oxcarbazepine in patient serums. Furthermore, the treated GSC spheroids were 82% smaller (mean volume 1.6 nL vs. 8.7 nL; p = 0.01 (live/deadTM fluorescence staining)), and the apoptotic events increased by more than 50% (caspase-3/7 activity; p = 0.006). Taken together, this drug screen of a large series of antiepileptic drugs identified oxcarbazepine as a potent proapoptotic drug in IDHmut GSCs, which combines antiepileptic and antineoplastic properties to treat this seizure-prone patient population.

show abstract

Non-dominant, Tumor-related Temporal Lobe Epilepsy

Herlopian

2024

Epilepsy Surgery: A Practical Case-Based Approach

View full text Add to dashboard Cite

Outcomes of tumour related epilepsy in a specialised epilepsy surgery unit

Cited by 4 publications

References 33 publications

Epidemiological Characteristics of Primary Tumors 0f the Central Nervous System According to Anatomical Location and Type of Lesion in a Level IV Hospital in Colombia in the Period Between 2008-2019

Epidemiological Characteristics of Primary Tumors 0f the Central Nervous System According to Anatomical Location and Type of Lesion in a Level IV Hospital in Colombia in the Period Between 2008-2019

The Antiepileptic Drug Oxcarbazepine Inhibits the Growth of Patient-Derived Isocitrate Dehydrogenase Mutant Glioma Stem-like Cells

Non-dominant, Tumor-related Temporal Lobe Epilepsy

Contact Info

Product

Resources

About